Protalix BioTherapeutics, Inc. (DE) (PLX) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Protallix Biotherapeutics First Quarter 2025 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I will now turn the conference over to our host, Mike Moyer of LifeSci Advisors, Investor Relations for Protallix. Thank you. Please go ahead. Thank you, operator, and welcome to the Protallix Biotherapeutics First Quarter. 2025 Financial Results and Business Update Conference Call. With me today are Dror Bashan, President and CEO of Bratallix, and Ayal Rubin, Senior Vice President and Chief Financial Officer. Press release announcing the financial results for the quarter and corporate updates was issued this morning and is available now on the Bratallix website. Please take a moment to read the disclaimer and forward-looking statements in the press release. The earnings released in this teleconference include forward-looking statements These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in Protox's filings with the U.S. Securities and Exchange Commission. I will now turn the call over to Mr. Michaud. Sure. Thank you, Mike. And thank you, everyone, for joining for our first quarter of 2025 financial results and business update quote. I will begin with the reviewing of our accomplishments over the quarter in recent weeks. Following my remarks, Eyal will provide a detailed review of our financial results. And then we will open the line for your questions, of course. With another solid quarter, with an increase in revenues from selling goods compared to the same period last year...